Liquid pharmaceutical formulations of apixaban

Abstract

The present disclosure provides liquid pharmaceutical formulations, suitable for oral administration, that comprise apixaban and glycerol. Certain embodiments of the present disclosure provide liquid pharmaceutical formulations, suitable for oral administration, that contain glycerol and an amount of apixaban in the solution phase of the formulations of from 0.5 mg / ml to 2.2 mg / ml.

Description

New PCT patent application TAP Pharmaceuticals AG Vossius Ref.: AG3544 PCT BS LIQUID PHARMACEUTICAL FORMULATIONS OF APIXABAN

[0001] The present application claims the benefit of priority of United States patent application serial number 18 / 103,173, filed on January 30, 2023, and of European patent application number EP 23205073.2, filed on October 23, 2023, each of which is incorporated herein by reference in its entirety. FIELD

[0002] The instant disclosure provides liquid pharmaceutical formulations, suitable for oral administration, that comprise apixaban and that exhibit advantageous solubility properties therefor, and methods of making and using same. BACKGROUND

[0003] Apixaban is an anticoagulant that functions as an inhibitor of trypsin-like serine protease enzymes, including factor Xa. Apixaban is the active pharmaceutical ingredient in ELIQUIS® tablets, approved by the United States Food and Drug Administration (“USFDA”) and other regulatory authorities throughout the world. USFDA indications for ELIQUIS® include reducing the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation, prophylaxis of deep vein thrombosis that may lead to pulmonary embolism in patients who have undergone hip or knee replacement surgery, treating deep vein thrombosis and pulmonary embolism, and reducing in the risk of recurrent deep vein thrombosis and pulmonary embolism following initial therapy.

[0004] Apixaban is a lactam containing compound and chemically described as 1-(4- methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-4,5,6,7-tetrahydro-1H-pyrazolo[3,4- c]pyridine-3-carboxamide with the molecular formula C25H25N5O4. The chemical structure of apixaban is:

[0005] United States Patent No. 9,452,134 (the “’134 patent”) teaches that apixaban has low aqueous solubility (i.e., 0.04 mg / ml) and identifies that as a major hurdle to the development of a liquid formulation of apixaban. The ‘134 patent recognizes that liquid formulations are important for administration of apixaban to the pediatric population and to adults who are unable to swallow a solid dosage form. The ‘134 patent determined that a concentration of 0.4 mg / ml of apixaban in an oral liquid formulation adequately supports a desired dosage range of from 0.04 mg to 5.0 mg with administered volumes ranging from 0.10 ml to 12.5 ml (i.e., volumes that can be both accurately measured and conveniently administered). The ‘134 patent states that a minimum solubility of apixaban of 0.50 mg / ml at 15-25°C can provide a robust formulation at the 0.4 mg / mL target concentration. Since such solubility would help to maintain apixaban in a dissolved state within the range of temperatures to which the formulation may be exposed during shipping and handling by patients. The ‘134 patent discloses that its liquid formulations of apixaban comprise a vehicle in which the solubility of apixaban is at least 0.50 mg / ml. The ‘134 patent teaches that its vehicle for apixaban contains water and at least two solubilizers that are selected from the group consisting of a non-ionic surfactant, an ionic surfactant, a hydrophilic polymer, ethanol, a polyhydric alcohol, a polyethylene glycol, and a carbohydrate.

[0006] The ‘134 patent describes non-ionic surfactants as non-ionizable, surface-active agents that reduce the surface tension of a liquid and thus allows it to foam or wet a solid. Examples of non- ionic surfactants for use in apixaban liquid formulations taught by the ‘134 patent are polysorbates, poloxamers, polyoxyethylene castor oil derivatives, polyoxyglycerides, vitamin E polyethylene glycol succinate, and macrogol 15 hydroxy stearate. The ‘134 patent describes ionic surfactants as surface-active agents with ionizable group(s) which reduce the surface tension of a liquid and thus allows it to foam or wet a solid. Examples of ionic surfactants for use in apixaban liquid formulation taught by the ‘134 patent are sodium lauryl sulfate and docusate sodium.

[0007] The ‘134 patent describes hydrophilic polymers as high molecular weight compounds derived from the addition of many smaller units and having a strong affinity for water. Examples of hydrophilic polymers for use in the apixaban liquid formulation taught by the ‘134 patent are povidone, copovidone, hydroxypropyl cellulose, and hydroxypropyl methylcellulose. The ‘134 patent describes polyhydric alcohols as compounds with more than one hydroxyl group. Examples of polyhydric alcohols for use in the apixaban liquid formulation taught by the ‘134 patent are glycerin, propylene glycol, sorbitol, and mannitol.

[0008] The ‘134 patent describes polyethylene glycol as polymers of ethylene glycol formed by the reaction of ethylene oxide and water. Examples of polyethylene glycols for use in the apixaban liquid formulation taught by the ‘134 patent are polyethylene glycol 200, 300, and 400. The ’134patent describes carbohydrates as a class of organic compounds that are polyhydroxy aldehydes or ketones. Examples of carbohydrates that for use in the apixaban liquid formulation taught by the ‘134 patent are fructose, sucrose, and lactose.

[0009] International Patent Cooperation Treaty Publication WO2022 / 123074 (“the ‘074 publication”) teaches that liquid medicaments intended for the oral administration are advantageously administrated in small dose volumes of less than 10 ml, especially for geriatric, pediatric, or bedridden patients, e.g. patients undergoing hip surgery and for patients who usually receive their medication through feeding tubes. The ‘074 publication teaches pharmaceutical formulations suitable for oral administration that contain apixaban at concentrations within the range of 0.25 mg / ml to 10 mg / ml and that have as a dose volume of equal to or less than: 10 ml, 5 ml, 4 ml, 3 ml, 2 ml, or 1 ml. The ‘074 publication teaches that such apixaban formulations which also contain propylene glycol in amounts of more than: 35% (w / v), 40% (w / v), 45% (w / v), 50% (w / v), or 55% (w / v), based on the total formulation, dissolves apixaban in small vehicle volumes, resulting in a solution which remains stable and is free of precipitation / crystallization.

[0010] The ‘074 publication teaches that its Example Formulations 16-20 comprise, in 100% propylene glycol, apixaban in the following concentrations, respectively: 0.25 mg / ml, 0.5 mg / ml, 1.0 mg / ml, 1.5 mg / ml, 1.85 mg / ml, and 2.0 mg / ml. The ‘074 publication teaches that, at 20°C, the apixaban is soluble in its Example Formulations 16-19 (i.e., up to 1.85 mg / ml apixaban) and that, at 20°C, the apixaban is partially soluble in its Example Formulation 20 (i.e., 2.0 mg / ml apixaban). (See Table 1 of the ‘074 publication, which for ready reference is reproduced below as Table A.) The ’074 publication also teaches that its Example Formulations 7-11 comprise, in 35% propylene glycol and 60% glycerol, apixaban in the following concentrations, respectively: 0.25 mg / ml, 0.5 mg / ml, 1.0 mg / ml, 1.5 mg / ml, and 2.0 mg / ml. The ‘074 publication teaches that, at 20°C, the apixaban is soluble in its Example Formulations 7 and 8 (i.e., up to 0.5 mg / ml apixaban) and that, at 20°C, the apixaban is partially soluble in its Example Formulation 9 (i.e., 1.0 mg / ml apixaban) and that, at 20°C, the apixaban is in soluble in its Example Formulations 9 and 11 (i.e., 1.5 mg / ml and 2.0 mg / ml apixaban, respectively). (See Table 1 of the ‘074 publication, which for ready reference is reproduced below as Table A.) The ‘074 publication therefore teaches that the solubility of apixaban is essentially cut in half in formulations that contain 60% glycerol and 35% propylene glycol as compared to formulations that contain no glycerol and 100% propylene glycol.Table A The ‘074 publication’s example 7-38 apixaban compositions, solubilities Example Formulation Concentration Temp Remarks No (mg / ml) (°C) 7 Apixaban + 35 % 0.25 20 Soluble Propylene Glycol +60% Glycerol anh. 8 Apixaban + 35 % 0.5 20 Soluble Propylene Glycol +60% Glycerol anh. 9 Apixaban + 35 % 1.0 20 Partially Propylene Glycol + soluble 60% Glycerol anh. 10 Apixaban + 40 % 1.5 20 Insoluble Propylene Glycol + 60% Glycerol anh. 11 Apixaban + 40 % 2.0 20 Insoluble Propylene Glycol + 60% Glycerol anh. 12 Apixaban + 40 % 1.0 35 Partially Propylene Glycol + soluble 60% Glycerol anh. 13 Apixaban + 40 % 1.0 40 Soluble Propylene Glycol + 60% Glycerol anh. 14 Apixaban + 40 % 1.5 45 Soluble Propylene Glycol + 60% Glycerol anh. 15 Apixaban + 40 % 2.0 45 Soluble Propylene Glycol + 60% Glycerol anh. 16 Apixaban + 100 % 0.25 20 Soluble Propylene Glycol 17 Apixaban + 100 % 0.5 20 Soluble Propylene Glycol 18 Apixaban + 100 % 1.0 20 Soluble Propylene Glycol 19 Apixaban + 100 % 1.85 20 Soluble Propylene Glycol 20 Apixaban + 100 % 2.00 20 Partially Propylene Glycol soluble 21 Apixaban + 100 % 2.50 35 Soluble Propylene Glycol 22 Apixaban + 100 % 3.33 35 Soluble Propylene Glycol 23 Apixaban + 100 % 5.00 45 Soluble Propylene Glycol 24 Apixaban + 100 % 10.00 55 Soluble Propylene Glycol 25 Apixaban + 40 % 0.25 20 Soluble Propylene Glycol +3% PEG-200 + 57% Glycerol anh. 26 Apixaban + 40 % 0.5 20 Soluble Propylene Glycol +3% PEG-200 + 57% Glycerol anh.27 Apixaban + 97% 3.00 20 Soluble Propylene Glycol + 3% PEG-200 28 Apixaban + 97% 3.33 20 Partially Propylene Glycol + soluble 3% PEG-200 29 Apixaban + 97% 3.33 35 Soluble Propylene Glycol + 3% PEG-200 30 Apixaban + 97% 5.00 20 Partially Propylene Glycol + soluble 3% PEG-200 31 Apixaban + 97% 5.00 20 Partially Propylene Glycol + soluble 3% PEG-200 32 Apixaban + 97% 5.00 45 Soluble Propylene Glycol + 3% PEG-200 33 Apixaban + 45% 5.00 35 Partially Propylene Glycol + soluble 55% Sorbitol solution 34 Apixaban + 45% 5.00 45 Soluble Propylene Glycol + 55% Sorbitol solution 35 Apixaban + 45% 5.00 35 Partially Propylene Glycol + soluble 55% Fructose solution 36 Apixaban + 45% 5.00 45 Soluble Propylene Glycol + 55% Fructose solution 37 Apixaban + 45% 5.00 35 Partially Propylene Glycol + soluble 55% Maltitol solution 38 Apixaban + 45% 5.00 45 Soluble Propylene Glycol + 55% Maltitol solution SUMMARY

[0011] Certain embodiments of the disclosure provide liquid pharmaceutical formulations, suitable for oral administration, that comprise apixaban and glycerol. In some of such embodiments, the amount of glycerol is sufficient to result in from 0.5 mg / ml to 1.75 mg / ml of the apixaban being in the solution phase of the formulation, at 20 hours after the formulation’s manufacture when the formulation is kept at 25ºC± 2ºC. In some of such embodiments, the amount of glycerol is sufficient to result in from 0.5 mg / ml to 1.75 mg / ml of the apixaban being in the solution phase of the formulation, when the formulation is kept at 25ºC± 2ºC. In some of such embodiments, the formulations are free of added: polysorbate, povidone, hydroxypropyl cellulose, or hydroxypropyl methylcellulose; propylene glycol, sorbitol, mannitol, fructose, sucrose, andlactose. In some of such embodiments, the formulations are free of: polysorbate, povidone, hydroxypropyl cellulose, or hydroxypropyl methylcellulose; propylene glycol, sorbitol, mannitol, fructose, sucrose, and lactose. In some of such embodiments the amount of apixaban in the solution phase of the formulation is from 0.75 mg / ml to 1.75 mg / ml, from 1.0 mg / ml to 1.75 mg / ml, or 1.0 mg / ml. In some of such embodiments the amount of glycerol is from 370 mg / ml to 1260 mg / ml, from 462.5 mg / ml to 1260 mg / ml, from 740 mg / ml to 1260 mg / ml, or 1260 mg / ml. In some of such embodiments the formulations are free of added: (i) polysorbate, poloxamer, polyoxyethylene castor oil, polyoxyglyceride, vitamin E polyethylene glycol succinate, macrogol 15 hydroxy stearate, sodium lauryl sulfate, and docusate sodium; (ii) povidone, hydroxypropyl cellulose, and hydroxypropyl methylcellulose; (iii) propylene glycol, sorbitol, and mannitol; and (iv) fructose, sucrose, and lactose. In some of such embodiments the formulations are free of: (i) polysorbate, poloxamer, polyoxyethylene castor oil, polyoxyglyceride, vitamin E polyethylene glycol succinate, macrogol 15 hydroxy stearate, sodium lauryl sulfate, and docusate sodium; (ii) povidone, hydroxypropyl cellulose, and hydroxypropyl methylcellulose; (iii) propylene glycol, sorbitol, and mannitol; and (iv) fructose, sucrose, and lactose. In some of such embodiments the formulations are free of added surfactant, hydrophilic polymer, polyhydric alcohol other than the glycerol, and carbohydrate. In some of such embodiments the formulations are free of surfactant, hydrophilic polymer, polyhydric alcohol other than the glycerol, and carbohydrate.

[0012] Certain embodiments of the disclosure provide liquid pharmaceutical formulations, suitable for oral administration, that contain a therapeutically effective amount of apixaban; and an amount of glycerol sufficient to result in from 0.5 mg / ml to 1.75 mg / ml of the apixaban being in the solution phase of the formulation, at 20 hours after the formulation’s manufacture when the formulation is kept at 25ºC± 2ºC. In some of such embodiments the formulations are free of added: polysorbate, povidone, hydroxypropyl cellulose, or hydroxypropyl methylcellulose; propylene glycol, sorbitol, mannitol, fructose, sucrose, and lactose. In some of such embodiments the formulations are free of: polysorbate, povidone, hydroxypropyl cellulose, or hydroxypropyl methylcellulose; propylene glycol, sorbitol, mannitol, fructose, sucrose, and lactose. In some of such embodiments the amount of apixaban in the solution phase of the formulation is from 0.75 mg / ml to 1.75 mg / ml, from 1.0 mg / ml to 1.75 mg / ml, or 1.0 mg / ml. In some of such embodiments the amount of glycerol is from 370 mg / ml to 1260 mg / ml, from 462.5 mg / ml to 1260 mg / ml, from 740 mg / ml to 1260 mg / ml, or 1260 mg / ml. In some of such embodiments the formulations are free of added: (i) polysorbate, poloxamer, polyoxyethylene castor oil, polyoxyglyceride, vitamin E polyethylene glycol succinate, macrogol 15 hydroxy stearate, sodium lauryl sulfate, and docusate sodium; (ii) povidone, hydroxypropyl cellulose, and hydroxypropyl methylcellulose; (iii)propylene glycol, sorbitol, and mannitol; and (iv) fructose, sucrose, and lactose. In some of such embodiments the formulations are free of: (i) polysorbate, poloxamer, polyoxyethylene castor oil, polyoxyglyceride, vitamin E polyethylene glycol succinate, macrogol 15 hydroxy stearate, sodium lauryl sulfate, and docusate sodium; (ii) povidone, hydroxypropyl cellulose, and hydroxypropyl methylcellulose; (iii) propylene glycol, sorbitol, and mannitol; and (iv) fructose, sucrose, and lactose. In some of such embodiments the formulations are free of added surfactant, hydrophilic polymer, polyhydric alcohol other than the glycerol, and carbohydrate. In some of such embodiments the formulations are free of surfactant, hydrophilic polymer, polyhydric alcohol other than the glycerol, and carbohydrate.

[0013] Certain embodiments of the present disclosure provide methods of (i) reducing the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation, (ii) reducing the risk of deep vein thrombosis leading to pulmonary embolism in patients who have undergone hip or knee replacement surgery, (iii) treating deep vein thrombosis and pulmonary embolism, or (iv) treating recurrent deep vein thrombosis and pulmonary embolism, that include the step of orally administering a formulation of the disclosure to a subject presenting nonvalvular atrial fibrillation, deep vein thrombosis or pulmonary embolism or who has undergone hip or knee replacement therapy. In some of such embodiments, the formulation is administered to the subject once daily and wherein the formulation contains a total amount of apixaban of from 1 mg to 10 mg.

[0014] Certain embodiments of the present disclosure provide methods for preparing liquid formulations of apixaban that involve adding glycerol to a vessel with stirring or other mixing and heating to 80°C ± 5°C; adding apixaban to the glycerol with continued stirring or other mixing at 80°C ± 5°C and cooling the mixture with continued stirring until the resulting suspension of apixaban in glycerol reaches 55°C (at least one hour) and becomes a clear solution; and allowing the resultant solution to stand and cool to room temperature (25°C±2°C).

[0015] Exemplary embodiment A.1 of the disclosure provides a liquid pharmaceutical formulation, suitable for oral administration, that contains a therapeutically effective amount of apixaban; and an amount of glycerol sufficient to result in from 0.5 mg / ml to 1.70 mg / ml of the apixaban being in the solution phase of the formulation, at 24 hours after the formulation’s manufacture when the formulation is kept at 25ºC± 2ºC. Embodiment A.1 is free of added: polysorbate, povidone, hydroxypropyl cellulose, or hydroxypropyl methylcellulose; propylene glycol, sorbitol, mannitol, fructose, sucrose, and lactose. Exemplary embodiments A.2, A.3, and A.4 differ from embodiment A.1 by containing in their solution phase, respectively, from 0.75 mg / ml to 1.70 mg / ml apixaban, from 1.0 mg / ml to 1.70 mg / ml apixaban, or 1.0 mg / ml apixaban. Exemplary embodiments A.5, A.6, A.7, and A.8 differ from embodiments A.1-A.4 by containing,respectively, glycerol in an amount of from 370 mg / ml to 1260 mg / ml, from 462.5 mg / ml to 1260 mg / ml, from 740 mg / ml to 1260 mg / ml, or 1260 mg / ml. Exemplary embodiment A.9 differs from embodiments A.1-A.8 by being free of added surfactant, hydrophilic polymer, polyhydric alcohol other than the glycerol, and carbohydrate.

[0016] Exemplary embodiment B.1 of the disclosure provides a liquid pharmaceutical formulation, suitable for oral administration, that contains from 462.5 mg / ml to 1260 mg / ml glycerol and from 0.75 mg / ml to 1.75 mg / ml apixaban that is at least 95% in the solution phase of the formulation, at 20 hours after the formulation’s manufacture when the formulation is kept at 25ºC± 2ºC. Embodiment B.1 is free of added: polysorbate, povidone, hydroxypropyl cellulose, or hydroxypropyl methylcellulose; and of propylene glycol, sorbitol, mannitol, fructose, sucrose, and lactose. Exemplary embodiments B.2, B.3, and B.4 differ from embodiment B.1 by containing in their solution phase, respectively, from 1.0 mg / ml to 1.70 mg / ml apixaban, from 1.0 mg / ml to 1.25 mg / ml apixaban, or 1.0 mg / ml apixaban, at least 97% of such amounts of apixaban being in the solution phase of the formulations. Exemplary embodiments B.5 and B.6 differ from embodiments B.1-B.4 by containing, respectively, glycerol in an amount of from 740 mg / ml to 1260 mg / ml or 1260 mg / ml. Exemplary embodiments B.7, B.8, and B.9 differ from embodiments B.1-B.6 by containing, respectively, at least 98% or at least 99% of the apixaban in solution. Exemplary embodiment B.10 differs from embodiments B.1-B.9 by being free of added surfactant, hydrophilic polymer, polyhydric alcohol other than the glycerol, and carbohydrate.

[0017] Exemplary embodiment C.1 of the disclosure provides a liquid pharmaceutical formulation, suitable for oral administration, that contains from 462.5 mg / ml to 1260 mg / ml glycerol and from 0.75 mg / ml to 1.70 mg / ml apixaban that is at least 95% in the solution phase of the formulation, at 24 hours after the formulation’s manufacture when the formulation is kept at 25ºC± 2ºC. Embodiment C.1 is free of added: polysorbate, povidone, hydroxypropyl cellulose, or hydroxypropyl methylcellulose; and of propylene glycol, sorbitol, mannitol, fructose, sucrose, and lactose. Exemplary embodiments C.2, C.3, and C.4 differ from embodiment C.1 by containing in their solution phase, respectively, from 1.0 mg / ml to 1.70 mg / ml apixaban, from 1.0 mg / ml to 1.25 mg / ml apixaban, or 1.0 mg / ml apixaban, at least 97% of such amounts of apixaban being in the solution phase of the formulations. Exemplary embodiments C.5 and C.6 differ from embodiments C.1-C.4 by containing, respectively, glycerol in an amount of from 740 mg / ml to 1260 mg / ml or 1260 mg / ml. Exemplary embodiments C.7, C.8, and C.9 differ from embodiments C.1-C.6 by containing, respectively, at least 98% or at least 99% of the apixaban in solution. Exemplary embodiment C.10 differs from embodiments C.1-C.9 by being free of added surfactant, hydrophilic polymer, polyhydric alcohol other than the glycerol, and carbohydrate. Certainembodiments of the present disclosure provide methods of (i) reducing the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation, (ii) reducing the risk of deep vein thrombosis leading to pulmonary embolism in patients who have undergone hip or knee replacement surgery, (iii) treating deep vein thrombosis and pulmonary embolism, or (iv) treating recurrent deep vein thrombosis and pulmonary embolism, that include the step of orally administering a formulation according to any one of exemplary embodiments A.1-A.9, B.1-B.10, or C.1-C.10 of the disclosure to a subject presenting nonvalvular atrial fibrillation, deep vein thrombosis or pulmonary embolism or who has undergone hip or knee replacement therapy. In some of such embodiments, the formulation is administered to the subject once daily and wherein the formulation contains a total amount of apixaban of from 1 mg to 10 mg.

[0018] Certain embodiments of the disclosure provide liquid pharmaceutical formulations, suitable for oral administration, that contain apixaban (particularly a therapeutically effective amount of apixaban) and at least 60% w / v glycerol. In such formulations, from 0.75 mg / ml to 1.75 mg / ml of the apixaban is in the solution phase of the formulation, at 20 hours after the formulation’s manufacture when the formulation is kept at 25ºC± 2ºC. In some of such formulations, the amount of apixaban in the solution phase of the formulation is from 1.0 mg / ml to 1.75 mg / ml, or 1.0 mg / ml. Some of such formulations contain at least 70% glycerol, at least 80% glycerol, at least 90% glycerol, at least 95% glycerol, at least 97%, at least 99% glycerol, or the apixaban and balance glycerol.

[0019] Certain embodiments of the disclosure provide liquid pharmaceutical formulations, suitable for oral administration, that contain apixaban (particularly a therapeutically effective amount of apixaban) and at least 60% w / v glycerol. In such formulations, from 0.75 mg / ml to 1.75 mg / ml of the apixaban is in the solution phase of the formulation, when the formulation is kept at 25ºC± 2ºC. In some of such formulations, the amount of apixaban in the solution phase of the formulation is from 1.0 mg / ml to 1.75 mg / ml, or 1.0 mg / ml. Some of such formulations contain at least 70% glycerol, at least 80% glycerol, at least 90% glycerol, at least 95% glycerol, at least 97%, at least 99% glycerol, or the apixaban and balance glycerol. DETAILED DESCRIPTION

[0020] The present disclosure provides liquid pharmaceutical formulations of apixaban that are suitable for oral administration and that exhibit surprisingly advantageous high levels of apixaban solubilities not attainable prior to the instant disclosure. Such formulations of the disclosure are useful for reducing the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation, the prophylaxis of deep vein thrombosis that may lead to pulmonary embolism inpatients who have undergone hip or knee replacement surgery, treating deep vein thrombosis and pulmonary embolism, and reducing in the risk of recurrent deep vein thrombosis and pulmonary embolism following initial therapy.

[0021] In some formulations of the disclosure, the proportion of apixaban in the solution phase can be from 75% to 99%, from 80% to 99%, from 85% to 99%, from 90% to 99%, or from 95% to 99%. In some formulations of the disclosure, the proportion of apixaban in the solution phase can be from 75% to 98%, from 80% to 98%, from 85% to 98%, from 90% to 98%, or from 95% to 98%. In some formulations of the disclosure, the proportion of apixaban in the solution phase can be from 75% to 97%, from 80% to 97%, from 85% to 97%, from 90% to 97%, or from 95% to 97%.

[0022] Formulations as disclosed herein can “comprise” a list of ingredients, such list then being open to inclusion of further unspecified ingredients. Alternatively, formulations as disclosed herein can “consist of” a list of ingredients, meaning that the formulations include only the listed ingredients. Or, formulations as disclosed herein can “consist essentially of” the listed ingredients, meaning that the formulations include all of the listed ingredients, and may include as well any further ingredients that do not materially affect the utility of the formulation. Whenever reference is made to a formulation “comprising” certain ingredients, the present disclosure also relates to a formulation “consisting essentially of” the corresponding ingredients, and the disclosure likewise relates to a formulation “consisting of” the corresponding ingredients.

[0023] In some embodiments, formulations of the present disclosure contain apixaban, at concentrations in the overall formulation of from 0.5 mg / ml to 30 mg / ml and further exemplary concentrations include 0.5 mg / ml, 0.75 mg / ml, 1 mg / ml, 1.25 mg / ml, 1.5 mg / ml, 1.75 mg / ml, 2 mg / ml, 2.5 mg / ml, 3 mg / ml, 3.5 mg / ml, 4 mg / ml, 4.5 mg / ml, 5 mg / ml, 5.5 mg / ml, 6 mg / ml, 6.5 mg / ml, 7 mg / ml, 7.5 mg / ml, 8 mg / ml, 8.5 mg / ml, 9 mg / ml, 9.5 mg / ml, 10 mg / ml, 10.5 mg / ml, 11 mg / ml, 11.5 mg / ml, 12 mg / ml, 12.5 mg / ml, 13 mg / ml, 13.5 mg / ml, 14 mg / ml, 14.5 mg / ml, 15 mg / ml, 15.5 mg / ml, 16 mg / ml, 16.5 mg / ml, 17 mg / ml, 17.5 mg / ml, 18 mg / ml, 18.5 mg / ml, 19 mg / ml, 19.5 mg / ml, 20 mg / ml, 20.5 mg / ml, 21 mg / ml, 21.5 mg / ml, 22 mg / ml, 22.5 mg / ml, 23 mg / ml, 23.5 mg / ml, 24 mg / ml, 24.5 mg / ml, 25 mg / ml, 25.5 mg / ml, 26 mg / ml, 26.5 mg / ml, 27 mg / ml, 27.5 mg / ml, 28 mg / ml, 28.5 mg / ml, 29 mg / ml, 29.5 mg / ml, or 30 mg / ml as well as ranges between any two of said apixaban concentrations.

[0024] In some embodiments, formulations of the present disclosure contain apixaban, at concentrations in the solution phase of the formulation of from 0.5 mg / ml to 3 mg / ml and exemplary particular concentrations include 0.5 mg / ml, 0.75 mg / ml, 1 mg / ml, 1.25 mg / ml, 1.5mg / ml, 1.75 mg / ml, 2 mg / ml, 2.2 mg / ml, 2.5 mg / ml, 3 mg / ml, as well as ranges between any two of said apixaban in solution phase concentrations (e.g., from 0.5 mg / ml to 2.2 mg / ml).

[0025] In some embodiments, formulations of the disclosure have a proportion of the overall amount of apixaban present in the formulation that is dissolved (i.e., in solution) which is 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100%, or in a range between any two of such proportions.

[0026] In some embodiments as described above, a formulation of the disclosure can consist of the apixaban and glycerine (the terms “glycerine” and “glycerin”, as used herein, are synonyms of glycerol). In some embodiments, a formulation of the disclosure can consist of the apixaban, glycerol and a pH adjusting agent as described below. In any such embodiments, the pH of the formulation can be from 6 to 11 as described below. In some embodiments, a formulation of the disclosure can consist of the apixaban, glycerol, a pH adjusting agent as described below and one or more of a sweetener, flavorant, polymer, surfactant, tonicity agent and preservative as described below.

[0027] Glycerols useful in formulations of the disclosure include glycerol USP Grade (1,2,3 - Propanetriol), a colorless, odorless liquid available at a minimum 96.0% or a minimum 99.5% glycerol by assay. Commercially available glycerols include 99.9% glycerol by Puratin, 99.7% glycerol by Optim, 100% glycerol by JT Baker, 99.5% glycerol by MP Biomedicals, 99.4% glycerol by Honeywell, 99.8% glycerol by VWR Scientific, 99% glycerol by Spectrum, 100% glycerol by Millipore Sigma, 99% glycerol by Bean Town Chemical, 99.9% glycerol by Thermofischer Scientific Chemicals, 99.8% glycerol by Arcos Chemicals, 99.8% glycerol by VWR International. Also useful in formulations of the disclosure are glycerol esters that include glycerol 2 ethyl hexyl oleate, glycerol trioleate, glyceryl monooleate, and glyceryl monotallate.

[0028] In some embodiments, formulations of the disclosure can include a sweetener. Sweeteners useful in the formulations of the present disclosure include acesulfame-K, advantame, alitame, aspartame, brazzein, carrelame, curculin, cyclamic acid, corn syrup (e.g., high fructose corn syrup), cyclamate, dihydrochalchone, erythritol, fructose, galactose, glucose, glycerin, glycine, glycyrrhizic acid, hydrogenated glucose syrup, hydrogenated starch hydrolysate, isomalt, lactitol, lactose, mabilin, miraculin, maltitol, maltodextrin, maltose, monatin, mannitol, mannose, mogrosides, monellin, neohesperidin, pentadin, saccharin, sorbitol, stevia glycosides, sucralose, sucrose, tagatose, tryptophan, and xylitol. The sweetener may be present in liquid pharmaceutical formulations of the disclosure in weight to volume proportions of 0.10% w / v, 0.15% w / v, 0.20% w / v, 0.25% w / v, 0.30% w / v, 0.35% w / v, 0.40% w / v, 0.45% w / v, 0.50% w / v, 0.55% w / v, 0.60% w / v, 0.65% w / v, 0.70% w / v 0.75% w / v, 0.80% w / v, 80.5% w / v, 0.90% w / v, 0.95% w / v, 1% w / v,2% w / v, 3% w / v, 4% w / v, 5% w / v, 6% w / v, 7% w / v, 8% w / v, 9% w / v, 10% w / v or in a range between any two of said sweetener proportions. The formulations may comprise combinations of sweeteners, in amounts that individually or in aggregate achieve(s) the stated weight to volume proportions.

[0029] In some embodiments, formulations of the disclosure can include a flavorant. Flavorants useful in the formulations of the present disclosure include chocolate, vanilla, caramel, orange, lemon, lime, strawberry, raspberry, blueberry, cherry, cinnamon, and nutmeg. The flavorant may be present in liquid pharmaceutical formulations of the disclosure in weight to volume proportions of 0.10% w / v, 0.15% w / v, 0.20% w / v, 0.25% w / v, 0.30% w / v, 0.35% w / v, 0.40% w / v, 0.45% w / v, 0.50% w / v, 0.55% w / v, 0.60% w / v, 0.65% w / v, 0.70% w / v 0.75% w / v, 0.80% w / v, 80.5% w / v, 0.90% w / v, 0.95% w / v, 1% w / v, 2% w / v, 3% w / v, 4% w / v, 5% w / v, 6% w / v, 7% w / v, 8% w / v, 9% w / v, 10% w / v or in a range between any two of said flavorant proportions. The formulations may comprise combinations of flavorant, in amounts that individually or in aggregate achieve(s) the stated weight to volume proportions

[0030] In some embodiments, formulations of the disclosure can contain a pH adjusting agent and / or a buffer. Acidic pH adjusting agents useful in formulations of the disclosure include fumaric acid, formic acid, acetic acid, trichloroacetic acid, benzoic acid, oxalic acid, hydrofluoric acid, hydrogen sulfide, nitrous acid, sulfurous acid, phosphoric acid, and combinations thereof. Alkaline pH adjusting useful in formulations of the disclosure include sodium hydroxide, potassium hydroxide, calcium hydroxide, ammonium carbonate, ammonium hydroxide, ethanolamine, and trolamine. Buffers useful in formulations of the disclosure include acetic acid, sodium acetate, benzoic acid, sodium benzoate, boric acid, sodium borate, citric acid, sodium citrate, sodium phosphate, monobasic sodium phosphate, dibasic sodium phosphate, potassium phosphate, monobasic potassium phosphate, dibasic potassium phosphate, sodium acetate, lactic acid, a tartaric acid, sodium tartrate, sodium bicarbonate, sodium carbonate, tris(hydroxymethyl)aminomethane (“TRIS”), or a combination thereof. In such formulations, the buffer and / or pH adjusting agent are present in the formulations in amounts, alone or together, that are sufficient to cause the formulation to have a pH of from 6 to 11, for example pH 6, pH 6.1, pH 6.2, pH 6.3, pH 6.4, t pH 6.5, pH 6.6, pH 6.7, pH 6.8, pH 6.9, pH 7, pH 7.1, pH 7.2, pH 7.3, pH 7.4, pH 7.5, pH 7.6, pH 7.7, pH 7.8, pH 7.9, pH 8, pH 8.1, pH 8.2, pH 8.3, pH 8.4, pH 8.5, pH 8.6, pH 8.7, pH 8.8, pH 8.9, pH 9, pH 9.1, pH 9.2, pH 9.3, pH 9.4, pH 9.5, pH 9.6, pH 9.7, pH 9.8, pH 9.9, pH 10, pH 10.1, pH 10.2, pH 10.3, pH 10.4, pH 10.5, pH 10.6, pH 10.7, pH 10.8, pH 10.9, pH 11, as well as in a range between any two such pH values.

[0031] In some embodiments, formulations of the present disclosure are pourable. The viscosities of such formulations can range from 1 centipoise (“cps”) (i.e., the viscosity of water at room temperature) to 25,000 cps (i.e., the viscosity of chocolate syrup at room temperature); and exemplary particular viscosities of formulations of the disclosure include 1 cps, 25 cps, 50 cps, 75 cps, 100 cps, 150 cps, 200 cps (about the viscosity of maple syrup at room temperature), 250 cps, 300 cps, 400 cps, 500 cps, 600 cps, 700 cps, 800 cps, 900 cps, 1000 cps (about the viscosity of glycerin at room temperature), 1100 cps, 1200 cps, 1300 cps, 1400 cps, 1500 cps, 1600 cps, 1700 cps, 1800 cps, 1900 cps, 2000 cps, 2100 cps, 2200 cps, 2300 cps, 2400 cps, 2500 cps, 2600 cps, 2700 cps, 2800 cps, 2900 cps, 3000, 3500 cps, 4000 cps, 4500 cps, 5000 cps, 6000 cps, 7000 cps, 8000 cps, 9000 cps, 10,000 cps, 12,500 cps, 15,000 cps, 17,500 cps, 20,000, cps 22,500 cps, 25,000 cps (about the viscosity of chocolate syrup at room temperature), 27,500 cps, 30,000, cps as well as in a range between any two of said viscosities.

[0032] In some embodiments, formulations of the disclosure can contain a polymer. Non-ionic polymers useful in certain formulations of the disclosure include hydroxyethyl cellulose, hydroxypropylmethyl cellulose, methyl cellulose, carboxymethyl cellulose, polyvinyl pyrrolidone, and polyvinyl alcohol. Ionic polymers useful in certain formulations of the disclosure include polyacrylates (e.g., carbopols and carbomers), alginates, chitosans, hyaluronic acid, and xanthan gum. Such ionic and / or nonionic polymers may be present in formulations of the disclosure in weight to volume proportions of the overall formulation of 0.001% w / v, 0.005% w / v, 0.01% w / v, 0.05% w / v, 0.1% w / v, 0.25% w / v, 0.5% w / v, 0.75% w / v, 1.0% w / v, 1.25% w / v, 1.5% w / v, 1.75% w / v, 2.0% w / v, 2.25% w / v, 2.5% w / v, 2.75% w / v, 3.0% w / v, 3.25% w / v, 3.5% w / v 3.75% w / v, 4.0% w / v, 4.25% w / v, 4.5% w / v, 4.75% w / v, or 5.0% w / v, as well as in a range between any two of said polymer proportions. The formulations may comprise combinations of polymers, in amounts that individually or in aggregate achieve(s) the stated polymer proportions.

[0033] In some embodiments, formulations of the disclosure contain a surfactant. Surfactants useful in certain formulations of the disclosure include sodium lauryl sulfate, docusate sodium, phosphatidylcholine, lecithin, betaines, tyloxapol, polyoxyethylene sorbitan esters, such as polysorbate 20, polysorbate 60, and polysorbate 80; polyethoxylated castor oils, such as cremaphor, polyethoxylated hydrogenated castor oils, such as HCO-40; and poloxamers. Such surfactants may be present in formulations of the disclosure in weight to volume proportions of the overall formulation of 0.001% w / v, 0.005% w / v, 0.01% w / v, 0.05% w / v, 0.1% w / v, 0.2% w / v, 0.3% w / v, 0.4% w / v, 0.5% w / v, 0.6% w / v, 0.7% w / v, 0.8% w / v, 0.9% w / v, 1.0% w / v, 1.1% w / v, 1.2% w / v, 1.3% w / v, 1.4% w / v, 1.5% w / v, 1.6% w / v, 1.7% w / v, 1.8% w / v, 1.9% w / v, 2.0% w / v, or in a ranges between any two of said surfactant proportions. The formulations may comprisecombinations of surfactants, in amounts that individually or in aggregate achieve(s) the stated weight to volume proportions.

[0034] In some embodiments, formulations of the disclosure can contain a tonicity agent. Ionic tonicity agents useful in certain formulations of the disclosure include calcium chloride, magnesium chloride, potassium chloride, sodium chloride, sodium sulfate, and combinations thereof. Nonionic tonicity agents useful in the formulations described herein include mannitol, sorbitol, xylitol, erythritol, lactitol, maltitol, isomalt, and combinations thereof. The formulations may comprise tonicity agent in weight to volume proportions of the overall formulation of 0.001% w / v, 0.005% w / v, 0.01% w / v, 0.05% w / v, 0.1% w / v, 0.2% w / v, 0.3% w / v, 0.4% w / v, 0.5% w / v, 0.6% w / v, 0.7% w / v, 0.8% w / v, 0.9% w / v, 1.0% w / v, 1.1% w / v, 1.2% w / v, 1.3% w / v, 1.4% w / v, 1.5% w / v, 1.6% w / v, 1.7% w / v, 1.8% w / v, 1.9% w / v, 2.0% w / v, or in a range between any two of said tonicity agent proportions. The formulations may comprise combinations of tonicity agent, in amounts that individually or in aggregate achieve(s) the stated tonicity weight to volume proportions.

[0035] In some embodiments, formulations of the disclosure can contain a preservative. Preservatives useful in certain formulations of the disclosure include dibutylhydroxytoluene, benzalkonium chloride, benzyl alcohol, borates, parabens, cresols, benzoic acid, phenol, sorbic acid, benzethonium chloride, sodium chlorite and combinations thereof. The formulations may comprise preservative in weight to volume proportions of the overall formulation of 0.001% w / v, 0.005% w / v, 0.01% w / v, 0.05% w / v, 0.1% w / v, 0.25% w / v, 0.5% w / v, 0.75% w / v, 1.0% w / v, 1.25% w / v, 1.5% w / v, 1.75% w / v, 2.0% w / v, 2.25% w / v, 2.5% w / v, 2.75% w / v, 3.0% w / v, 3.25% w / v, 3.5% w / v 3.75% w / v, 4.0% w / v, 4.25% w / v, 4.5% w / v, 4.75% w / v, and 5.0% w / v, or in a range between any two of said preservative proportions. The formulations may comprise combinations of preservatives, in amounts that individually or in aggregate achieve(s) the stated weight to volume proportions.

[0036] As explained above, the formulations of the disclosure can be used, e.g., for reducing the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation, the prophylaxis of deep vein thrombosis that may lead to pulmonary embolism in patients who have undergone hip or knee replacement surgery, for treating deep vein thrombosis and pulmonary embolism, and for reducing in the risk of recurrent deep vein thrombosis and pulmonary embolism following initial therapy. Accordingly, the disclosure relates to the formulations provided herein for use in therapy, particularly for use in reducing the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation, for use in the prophylaxis of deep vein thrombosis that may lead to pulmonary embolism in patients who have undergone hip or knee replacement surgery,for use in treating deep vein thrombosis and pulmonary embolism, and / or for use in reducing in the risk of recurrent deep vein thrombosis and pulmonary embolism following initial therapy. In particular, the disclosure relates to the formulations provided herein for use in treating or preventing (or reducing the risk of) stroke, systemic embolism, deep vein thrombosis (e.g., recurrent deep vein thrombosis), or pulmonary embolism. The disclosure also relates to each one of the aforementioned uses, wherein the formulation is administered to a human subject, and / or wherein the formulation is administered orally, and / or wherein the formulation is administered once daily. The formulation may contain a total amount of apixaban of, for example, from 1 mg to 10 mg. The disclosure likewise relates to the use of the formulations provided herein in the preparation of a medicament for any of the aforementioned medical uses.

[0037] The patient or subject to be treated in accordance with the present disclosure may be an animal, particularly a mammal, more particularly a human.

[0038] The disclosure provides pharmaceutical formulations comprising apixaban. It will be understood that such formulations comprise a therapeutically effective amount of apixaban. EXAMPLES

[0039] Aspects of embodiments of the present disclosure may be further understood in light of the following examples, which should not be construed as limiting in any way. Objectives of the solubility and viscosity studies of the present disclosure were to evaluate the extent of apixaban solubility in a variety of liquid formulations. EXAMPLE 1

[0040] Apixaban solubility. Aqueous apixaban formulations 0277-034A, 0277-034B, and 0277- 034C comprised the ingredients set forth in Table 1.1 and were studied in the apixaban solubility experimental protocols described in this Example 1. Table 1.1 Apixaban formulations 0277-034A-C 0277-034A 0277-034B 0277-034C Ingredientmg / ml mg / ml mg / mlApixaban 3.0 3.0 3.0 Glycerol 1,260.0 1,260.0 1,260.0 Total 1,263.0 1,263.0 1,263.0

[0041] Apixaban batch manufacture. Formulations 0277-034A, 0277-034B, and 0277-034C were made as follows. Step 1: 126 g of glycerol was weighed into a glass beaker that had been zero tared to a laboratory scale. The glycerol was mixed with a magnetic stir rod and heated to 80°C ±5°C in the glass beaker. Step 2: 300 mg of apixaban was weighed and slowly added to the 80°C ± 5°C glycerol in the glass beaker from step 1, with continued stirring until the resulting suspension of apixaban in glycerol in the glass beaker reached 55°C (at least one hour). Step 3: The resultant solution from Step 2 was cooled to room temperature (25°C±2°C) in the glass beaker and then sealed with parafilm and transferred to analytical for further processing in controlled solubility study and relevant analytical testing (assay on representative mixed sample as-is and assay on supernatant liquid after filtration).

[0042] Apixaban HPLC analytical testing. The analytical methods and sampling steps performed on formulations 0277-034A, 0277-034B, and 0277-034C were conducted at room temperature (25°C ±2°C) and as set forth in Table 1.2. Table 1.2 Time point methods anda. 5-10 ml samples were collected from each of formulations 0277-034A, 0277- 034B, and 0277-034C immediately after batch manufacture Step 3. b. The apixaban HPLC assay was performed on each sample collected in T0 hour T0hours Step a. “as is.” The apixaban concentration (in mg / ml) for each sample was determined. c. 1 ml of each T0 hour Step a. sample was filtered through a 0.45-micron, PTFE filter and the filtrate was run in the apixaban HPLC assay. The apixaban concentration (in mg / ml) for each sample was determined. a. 5-10 ml samples were collected from each of formulations 0277-034A, 0277- 034B, and 0277-034C 12 hours after batch manufacture Step 3. b. The apixaban HPLC assay was performed on each sample collected in T12 hour Step a. “as is.” The apixaban concentration (in mg / ml) for each sample was T12hours determined. c. 1 ml of each T12 hour Step a. sample was filtered through a 0.45-micron, PTFE filter and the filtrate was run in the apixaban HPLC assay. The apixaban concentration (in mg / ml) for each sample was determined. d. Filtration supernatant assay results were compared to T0 results. a. 5-10 ml samples were collected from each of formulations 0277-034A, 0277- 034B, and 0277-034C 16 hours after batch manufacture Step 3. b. The apixaban HPLC assay was performed on each sample collected in T16 hour Step a. “as is.” The apixaban concentration (in mg / ml) for each sample was T16 hours determined. c. 1 ml of each T16 hour Step a. sample was filtered through a 0.45-micron, PTFE filter and the filtrate was run in the apixaban HPLC assay. The apixaban concentration (in mg / ml) for each sample was determined. d. Filtration supernatant assay results were compared to T12 results, if any result within ±5% of T12 was observed it was reported to formulator. a. 5-10 ml samples were collected from each of formulations 0277-034A, 0277- 034B, and 0277-034C 20 hours after batch manufacture Step 3. T20 hours b. The apixaban HPLC assay was performed on each sample collected in T20 hour Step a. “as is.” The apixaban concentration (in mg / ml) for each sample was determined.Filtrate fraction: Either: (i) the formulation was centrifuged at 5000 rpm for 20 min in an ultracentrifuge and the clear supernatant was collected; or (ii) in case a clear supernatant was not achieved with ultracentrifugation, the formulation was filtered with a 0.45 µm, PTFE filter. Then, 1ml of either (i) clear supernatant or (ii) filtrate was pipetted with a micropipette into a 20 ml volumetric flask and diluted to a final volume of 20 ml with diluent. Approximate apixaban concentration: Apixaban 0.1 mg / ml.

[0044] The chromatographic conditions for the apixaban high performance liquid chromatography (“HPLC”) assay employed in the present disclosure were as forth in Table 1.4. TABLE 1.4 Apixaban HPLC chromatographic parameters Chromatographic parametersEquipment and / or conditionsHPLC equipped with variable wavelength and / or PDA System (DAD) detector, column heater / chiller, and binary or a tertiary solvent pump Column Luna Phenyl hexyl, 150 mm x 4.6 mm, 3 µm Column Temperature25°CSample Tray TemperatureAmbientDetector WavelengthUV 210 nmPump Mode Gradient Flow Rate 8.0 ml / min Injection Volume 10 µl Apixaban retention timeAbout 4.6 minRun Time 15 minutes Time (min) Mobile phase A% Mobile phase B% 0 55 45 Gradient 3 55 45 10 20 80 11 55 45 15 55 45 Column wash Acetonitrile: water = 10:90 v / v and followed by solutions Acetonitrile: water = 90:10 v / v

[0045] The HPLC system was equilibrated with mobile phase for about 30 minutes. Iterative injections of diluent were made until a clean and reproducible baseline was achieved. The chromatograms were recorded and any peak eluting at the retention time of major peaks identified. Five replicate injections of apixaban working standard solution were made and chromatograms recorded. The average and relative standard deviation (% RSD) for the apixaban peak arearesponses were calculated from the five replicate injections of the apixaban working standard solution.

[0046] Two replicate injections of assay standard check solution were made and chromatograms recorded. The average peak area responses of the apixaban obtained from the two replicate injections of standard check solution were calculated and then the similarity factor was calculated. One injection of diluent was made before injecting each sample solutions. One injection of each sample solution was made, chromatogram recorded, and the apixaban peak area determined. The apixaban concentration in each sample solution was calculated. After six injections of sample solution and at the end of the sequence, one injection of diluent was made followed by one injection of working standard solution (bracketing). The % RSD of apixaban peak area obtained from the initial five injections of working standards and bracketing standard.

[0047] The equation employed to calculate percent assay for apixaban in the samples of the formulations of the present disclosure are set forth in Table 1.5. TABLE 1.5 Apixaban HPLC assay equations Assay for apixaban (on dried basis) %Assay =Aspl Wstd %Pstd 100 − %LOD sAstd×100mL×100%×td100%×100mLWspl×100%Pspl×100%100 − %LOD spl× 100% Assay for apixaban (in finished formulation) %Assay =Aspl Wstd %Pstd 100 − %LOD std 20mL 1Astd ×100mL ×100% ×100% ×1ml ×LC × 100%Assay for apixaban (in soluble fraction (mg / ml) of finished formulation) Soluble fraction = Aspl 20mlAstd × Std. conc ×1mlStd. conc(mg Wstd %Pstd 100 − %LOD stdmL) =100mL ×100% ×100%Where: Astd Average peak area of apixaban from first 5 replicate standards injections Aspl Peak Area of apixaban from sample injection Wstd Weight of apixaban used to prepare standard Wspl Weight of apixaban used to prepare sample % Pstd Percentage purity of apixaban in working standard % Pspl Percentage purity of apixaban in sample %LOD std % Loss on drying of Apixaban standard %LOD spl % Loss on drying of Apixaban sample

[0048] The HPLC assay experimental results for formulation 0277-034A, 0277-034B, and 0277- 034C are reported in Table 1.6.

Claims

CLAIMS What is claimed is:

1. A liquid pharmaceutical formulation, suitable for oral administration, that comprises: - apixaban; and - glycerol; wherein the formulation is free of added: - surfactant selected from the group consisting of a polysorbate, a poloxamer, a polyoxyethylene castor oil, a polyoxyglyceride, a vitamin E polyethylene glycol succinate, a macrogol 15 hydroxy stearate, a sodium lauryl sulfate, or a docusate sodium; - hydrophilic polymer selected from the group consisting of a povidone, a hydroxypropyl cellulose, or a hydroxypropyl methylcellulose; - polyhydric alcohol selected from the group consisting of a propylene glycol, a sorbitol, or a mannitol; and - carbohydrate selected from the group consisting of a fructose, a sucrose, or a lactose.

2. The formulation of claim 1, wherein the amount of glycerol in the formulation is sufficient to result in from 0.5 mg / ml to 1.75 mg / ml of the apixaban being in the solution phase of the formulation, at 20 hours after the formulation’s manufacture when the formulation is kept at 25ºC± 2ºC.

3. The formulation of claim 1 or 2, wherein the amount of apixaban in the solution phase of the formulation is from 0.75 mg / ml to 1.75 mg / ml.

4. The formulation of any one of claims 1 to 3, wherein the amount of apixaban in the solution phase of the formulation is from 1.0 mg / ml to 1.75 mg / ml.

5. The formulation of any one of claims 1 to 4, wherein the amount of apixaban in the solution phase of the formulation is 1.0 mg / ml.

6. The formulation of claim 1 or 2, wherein the amount of glycerol is from 370 mg / ml to 1260 mg / ml.

7. The formulation of claim 3, wherein the amount of glycerol is from 462.5 mg / ml to 1260 mg / ml.

8. The formulation of claim 4, wherein the amount of glycerol is from 740 mg / ml to 1260 mg / ml.

9. The formulation of claim 5, wherein the amount of glycerol is 1260 mg / ml.

10. The formulation of any one of claims 1 to 9, wherein the formulation is free of added: - polysorbate, poloxamer, polyoxyethylene castor oil, polyoxyglyceride, vitamin E polyethylene glycol succinate, macrogol 15 hydroxy stearate, sodium lauryl sulfate, and docusate sodium; - povidone, hydroxypropyl cellulose, and hydroxypropyl methylcellulose; - propylene glycol, sorbitol, and mannitol; and - fructose, sucrose, and lactose.

11. The formulation of any one of claims 1 to 10, wherein the formulation is free of added surfactant, hydrophilic polymer, polyhydric alcohol other than the glycerol, and carbohydrate.

12. The formulation of any one of claims 1 to 11 for use in (i) reducing the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation, (ii) reducing the risk of deep vein thrombosis leading to pulmonary embolism in patients who have undergone hip or knee replacement surgery, (iii) treating deep vein thrombosis and pulmonary embolism, or (iv) treating recurrent deep vein thrombosis and pulmonary embolism; wherein said use comprises orally administering the formulation to a subject presenting nonvalvular atrial fibrillation, deep vein thrombosis or pulmonary embolism or who has undergone hip or knee replacement therapy.

13. The formulation for use according to claim 12, wherein the formulation is administered to the subject once daily and wherein the formulation comprises a total amount of apixaban of from 1 mg to 10 mg.

14. A method of (i) reducing the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation, (ii) reducing the risk of deep vein thrombosis leading to pulmonary embolism in patients who have undergone hip or knee replacement surgery, (iii) treating deep veinthrombosis and pulmonary embolism, or (iv) treating recurrent deep vein thrombosis and pulmonary embolism, comprising orally administering the formulation of any one of claims 1 to 11 to a subject presenting nonvalvular atrial fibrillation, deep vein thrombosis or pulmonary embolism or who has undergone hip or knee replacement therapy.

15. The method of claim 14, wherein the formulation is administered to the subject once daily and wherein the formulation comprises a total amount of apixaban of from 1 mg to 10 mg.

16. Use of the formulation of any one of claims 1 to 11 in the manufacture of a medicament for (i) reducing the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation, (ii) reducing the risk of deep vein thrombosis leading to pulmonary embolism in patients who have undergone hip or knee replacement surgery, (iii) treating deep vein thrombosis and pulmonary embolism, or (iv) treating recurrent deep vein thrombosis and pulmonary embolism; wherein said medicament is for oral administration to a subject presenting nonvalvular atrial fibrillation, deep vein thrombosis or pulmonary embolism or who has undergone hip or knee replacement therapy.

17. The use of claim 16, wherein the medicament is for administration to the subject once daily and comprises a total amount of apixaban of from 1 mg to 10 mg.

18. A liquid pharmaceutical formulation, suitable for oral administration, that comprises: - apixaban; and - at least 60% w / v glycerol; wherein 0.75 mg / ml to 1.75 mg / ml of the apixaban is in the solution phase of the formulation, at 20 hours after the formulation’s manufacture when the formulation is kept at 25ºC± 2ºC.

19. The formulation of claim 18, wherein the amount of apixaban in the solution phase of the formulation is from 1.0 mg / ml to 1.75 mg / ml.

20. The formulation of claim 18 or 19, wherein the amount of apixaban in the solution phase of the formulation is 1.0 mg / ml.

21. The formulation of any one of claims 18 to 20, wherein the formulation comprises at least 70% w / v glycerol.

22. The formulation of any one of claims 18 to 21, wherein the formulation comprises at least 80% w / v glycerol.

23. The formulation of any one of claims 18 to 22, wherein the formulation comprises at least 90% w / v glycerol.

24. The formulation of any one of claims 18 to 20, wherein the formulation comprises the apixaban and balance glycerol.

25. The formulation of any one of claims 18 to 24 for use in (i) reducing the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation, (ii) reducing the risk of deep vein thrombosis leading to pulmonary embolism in patients who have undergone hip or knee replacement surgery, (iii) treating deep vein thrombosis and pulmonary embolism, or (iv) treating recurrent deep vein thrombosis and pulmonary embolism; wherein said use comprises orally administering the formulation to a subject presenting nonvalvular atrial fibrillation, deep vein thrombosis or pulmonary embolism or who has undergone hip or knee replacement therapy.

26. A method of (i) reducing the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation, (ii) reducing the risk of deep vein thrombosis leading to pulmonary embolism in patients who have undergone hip or knee replacement surgery, (iii) treating deep vein thrombosis and pulmonary embolism, or (iv) treating recurrent deep vein thrombosis and pulmonary embolism, comprising orally administering the formulation of any one of claims 18 to 24 to a subject presenting nonvalvular atrial fibrillation, deep vein thrombosis or pulmonary embolism or who has undergone hip or knee replacement therapy.

27. Use of the formulation of any one of claims 18 to 24 in the manufacture of a medicament for (i) reducing the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation, (ii) reducing the risk of deep vein thrombosis leading to pulmonary embolism in patients who have undergone hip or knee replacement surgery, (iii) treating deep vein thrombosis and pulmonary embolism, or (iv) treating recurrent deep vein thrombosis and pulmonary embolism; wherein said medicament is for oral administration to a subject presenting nonvalvular atrial fibrillation, deep vein thrombosis or pulmonary embolism or who has undergone hip or knee replacement therapy.

28. A formulation comprising 1 mg / ml apixaban and 1260 mg / ml glycerol.

29. The formulation of claim 28 for use in (i) reducing the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation, (ii) reducing the risk of deep vein thrombosis leading to pulmonary embolism in patients who have undergone hip or knee replacement surgery, (iii) treating deep vein thrombosis and pulmonary embolism, or (iv) treating recurrent deep vein thrombosis and pulmonary embolism; wherein said use comprises orally administering the formulation to a subject presenting nonvalvular atrial fibrillation, deep vein thrombosis or pulmonary embolism or who has undergone hip or knee replacement therapy.

30. A method of (i) reducing the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation, (ii) reducing the risk of deep vein thrombosis leading to pulmonary embolism in patients who have undergone hip or knee replacement surgery, (iii) treating deep vein thrombosis and pulmonary embolism, or (iv) treating recurrent deep vein thrombosis and pulmonary embolism, comprising orally administering the formulation of claim 28 to a subject presenting nonvalvular atrial fibrillation, deep vein thrombosis or pulmonary embolism or who has undergone hip or knee replacement therapy.

31. Use of the formulation of claim 28 in the manufacture of a medicament for (i) reducing the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation, (ii) reducing the risk of deep vein thrombosis leading to pulmonary embolism in patients who have undergone hip or knee replacement surgery, (iii) treating deep vein thrombosis and pulmonary embolism, or (iv) treating recurrent deep vein thrombosis and pulmonary embolism; wherein said medicament is for oral administration to a subject presenting nonvalvular atrial fibrillation, deep vein thrombosis or pulmonary embolism or who has undergone hip or knee replacement therapy.

Images